COMPANY PROFILE

Symbiotec Pharmalab

Explore full profile

Api manufacturing company that develops and markets research-based cortico steroids

IndiaFounded 2002Biotechnology

Valuation $100–500M Latest valuation · 2013

Headcount 1–2k Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Symbiotec Pharmalab

Symbiotec, based in Indore, Central India, specializes in the development, production, and marketing of research-based Cortico Steroids and Steroid Hormone Active Pharmaceutical Ingredients (APIs). The company leverages its collective expertise to create innovative pharmaceutical solutions aimed at enhancing patient health. Symbiotec serves a global clientele, including pharmaceutical companies and healthcare providers, operating in the highly specialized market of steroid APIs. The business model revolves around extensive research and development (R&D), followed by the commercialization of high-quality, reliable APIs. Revenue is generated through the sale of these APIs to various stakeholders in the healthcare industry. Symbiotec is committed to sustainable operations and responsible practices, contributing to community health initiatives such as the establishment of a Dialysis Unit at Madhav Srishti SevaNyas in Indore. The company’s strategic focus is on delivering advanced healthcare solutions while maintaining sustainable and ethical operations.

Source: Dealroom company data

At a glance

Status: Operational
Founded: 2002
Headquarters: India
Employees: 1,162
Open positions: None listed
Dealroom signal: 84.6/100
Sector: Biotechnology
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn X

Latest news

Press, funding announcements and product moves mentioning Symbiotec Pharmalab.

See all news

Funding history

2 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SECONDARY✓Other financing	Aug 2026	$8.8M	—	Think India Opportunities Master Fund · ValueQuest Investment Advisors · WhiteOak Capital Asset Management	↗
LATE VC✓Equity / VC	Oct 2013	$48M	$192M	Actis	—

Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Symbiotec Pharmalab website traffic

Latest recorded traffic for Symbiotec Pharmalab is 1.7K monthly website visits, up 54.5% over the last three months. Symbiotec Pharmalab's team grew 8% over the past year.

Latest monthly visits1.7K 3-month web change+54.5% 1-year team growth+8%

Monthly website visitsApr 2016–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
SISolid IOMaking immunotherapies accessible at scale.	Helsinki, Finland	Operational	13	$880K	$3.5M
FLflowboneHas engineered the first injectable biomaterial that stimulated the body's natural ossification process for rapid bone repair and strengthening	Lausanne, Switzerland	Operational
HEHealshapePersonalized, resorbable bioprosthesis for natural breast reconstruction	Nantes, France	Operational
CACarvolixThe new generation of minimally invasive implants to treat diseases of the heart, aorta, and urinary incontinence	Paris, France	Operational
EBExeliom BiosciencesDeveloping single bacterial strain drug candidates to deliver first-in-class microbiome-based therapeutics	Dijon, France	Operational
HPHcs PharmaA company specializing in cell imaging	Loos, France	Operational
EBEligo BioscienceEligo Bioscience is a biotechology company that develops a new class of biotherapeutics for microbiome precision-editing	Paris, France	Operational
ENEncefaDevelops biologics that specifically modulate a key age-related target, to fight neurodegenerative, auto-immune, and more broadly age-related diseases	Paris, France	Operational